Latest Ratios: P/E Ratio -1.8x · EV/EBITDA N/A · ROE -95.2%. (2015–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $519M | $530M | $600M | $1.1B | $180M | $374M | $461M | $568M | $968M | — | — |
| Enterprise Value | $766M | $777M | $425M | $934M | $-177692540 | $132M | $361M | $383M | $779M | — | — |
| P/E Ratio → | -1.81 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 6.87 | 7.01 | 59.25 | 659.71 | 29.14 | 248.25 | 268.76 | 195.48 | 925.87 | — | — |
| P/B Ratio | 2.91 | 2.97 | 1.40 | 10.05 | 0.60 | 1.19 | 2.19 | 2.23 | 4.72 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 10.28 | 41.98 | 549.82 | -28.69 | 87.45 | 210.50 | 131.79 | 745.00 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -27.8% | -27.8% | -1293.5% | 100.0% | 100.0% | 100.0% | -7765.2% | -3525.1% | -4520.4% | 40.4% | 60.6% |
| Operating Margin | -372.4% | -372.4% | -2385.6% | -10583.1% | -2307.0% | -9314.8% | -17675.4% | -8513.8% | -5503.7% | -1383.2% | -1186.1% |
| Net Profit Margin | -381.4% | -381.4% | -2180.5% | -12272.3% | -2403.0% | -9429.1% | -8285.4% | -4258.9% | -2976.5% | -1165.2% | -1035.5% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -95.2% | -95.2% | -81.9% | -101.6% | -48.6% | -54.3% | -61.1% | -53.8% | -17.9% | -22.8% | -48.8% |
| ROA | -42.0% | -42.0% | -38.1% | -48.1% | -33.2% | -40.6% | -47.5% | -47.5% | -17.0% | -21.6% | -44.2% |
| ROIC | -62.3% | -62.3% | -204.1% | — | -1865.4% | -116.3% | -253.0% | -433.4% | -394.8% | -407.9% | -161.7% |
| ROCE | -45.5% | -45.5% | -45.9% | -46.4% | -34.8% | -44.0% | -112.4% | -102.4% | -33.0% | -26.8% | -55.1% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.97 | 1.97 | 0.12 | 0.48 | 0.08 | 0.22 | 0.26 | 0.10 | 0.00 | 0.00 | 0.01 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 1.39 | -0.41 | -1.67 | -1.20 | -0.77 | -0.48 | -0.73 | -0.92 | -0.96 | -0.91 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -7.08 | -7.08 | -25.91 | -3.62 | -15.68 | -127.54 | — | — | -4107.60 | — | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.94 | 5.94 | 10.88 | 6.15 | 9.18 | 12.15 | 5.77 | 9.98 | 15.91 | 28.31 | 11.31 |
| Quick Ratio | 5.48 | 5.48 | 10.81 | 6.15 | 9.18 | 12.15 | 5.77 | 9.98 | 15.73 | 28.31 | 11.31 |
| Cash Ratio | 4.09 | 4.09 | 9.68 | 5.35 | 8.25 | 10.87 | 4.58 | 8.46 | 15.12 | 27.23 | 10.26 |
| Asset Turnover | — | 0.13 | 0.01 | 0.00 | 0.01 | 0.00 | 0.01 | 0.01 | 0.00 | 0.01 | 0.04 |
| Inventory Turnover | 2.91 | 2.91 | 34.08 | — | — | — | — | — | 21.87 | — | — |
| Days Sales Outstanding | — | 366.09 | 1739.88 | 225.06 | 1707.50 | 16.47 | 6317.80 | 3831.24 | 3234.69 | 1019.97 | 656.22 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.3% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.3% | — | — |
| Shares Outstanding | — | $266M | $255M | $174M | $95M | $72M | $52M | $43M | $32M | $14M | $14M |
Includes 30+ ratios · 11 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying AUTL stock.
Autolus Therapeutics plc's current P/E ratio is -1.8x. This places it at the 50th percentile of its historical range.
Autolus Therapeutics plc's return on equity (ROE) is -95.2%. The historical average is -56.6%.
Based on historical data, Autolus Therapeutics plc is trading at a P/E of -1.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Autolus Therapeutics plc has -27.8% gross margin and -372.4% operating margin.
Key Metrics
Top Statement Risk
Rapid cash depletion amid scaling losses
Metrics are mathematically derived from official filings.
Valuation Reflects Speculative Growth Premium
Autolus's P/S ratio of 8.24, as reported in recent market data, appears elevated for a company with a -85.6% net margin, suggesting the market is pricing in significant future revenue growth that has yet to translate into profitability.
The P/B ratio of 3.50 is notable given the severe erosion of book value, with shareholders' equity down 87% since Q1 2024. This valuation disconnect implies investors are valuing the company on its pipeline and commercial potential rather than its current asset base or earnings power. The negative P/E is a mathematical artifact of losses, making it an irrelevant metric for this stage of the company's lifecycle.
Gross Margin Volatility Masks Underlying Losses
The swing in gross margin from -99.9% in Q1 2025 to 55.2% in Q2 2026, as per the company's financial statements, appears driven by initial production scale and inventory dynamics rather than sustainable operational efficiency.
The operating margin remains deeply negative at -95.9%, indicating that SG&A and R&D expenses are scaling far ahead of revenue. This suggests the company is in a classic commercial launch phase where cost structure is not yet aligned with revenue generation. The net margin of -85.6% confirms that core operations are not yet self-sustaining.
Capital Returns Deeply Negative Amid Scaling
Autolus's ROIC of -146.8% in Q2 2026, based on the reported quarterly data, indicates that the company is destroying significant value for each dollar of invested capital deployed.
The consistently negative ROIC and ROE trends over the past ten quarters confirm that the business model is not yet generating returns. The drivers are clearly margin-based, as asset turnover remains extremely low (0.09), reflecting the nascent stage of commercial operations. This pattern is typical for pre-profit biotech firms but underscores the critical need for a path to positive returns.
Working Capital Cycle Reflects Launch Phase Chaos
The cash conversion cycle of 271 days in Q2 2026, as reported in the company's financials, is driven by a very high days inventory outstanding of 148, suggesting potential challenges in matching production with initial commercial demand.
The DSO of 130 days indicates extended collection periods, which may be a function of payer mix and reimbursement timelines for a new therapy. The extremely low DPO of 7 days suggests the company has minimal leverage with suppliers, likely due to its small scale and need for reliable input supply. This inefficient working capital structure ties up cash that is already scarce.
Leverage Fluctuates with Episodic Financing
The debt-to-equity ratio of 1.12 in Q2 2026, according to the company's balance sheet, represents a significant increase from 0.19 in Q2 2025, indicating a shift towards debt financing as equity has eroded.
The interest coverage ratio of -13.45 confirms that operating losses are insufficient to service even the current debt load. The volatility in total debt levels suggests episodic reliance on debt markets rather than a stable capital structure. This pattern increases refinancing risk, especially if the company's cash burn continues to deplete its liquidity buffer.
The Misleading Signal of Current Ratio
The current ratio of 4.89 in Q2 2026, as reported in the company's financial statements, is the most commonly misapplied metric for Autolus, as it obscures the rapid pace of cash depletion and the operational cash burn.
While a current ratio above 4 appears strong, it is misleading because the asset base is dominated by cash that is being consumed at an accelerating rate. The ratio does not reflect the negative free cash flow margin of -56.9% or the fact that the company's primary 'asset' is a depleting cash pile. A more appropriate metric for assessing near-term viability is the monthly cash burn rate relative to remaining liquidity.